Agenus Inc., an immune-oncology company developing immune checkpoint antibodies, cancer vaccines and adoptive cell therapies, achieved a cash milestone from Incyte for the initiation of a Phase I trial of INCAGN2385, an anti-LAG-3 antibody discovered by Agenus. Agenus received a $5 million payment and is eligible to receive as much as an additional $505 million in potential development, regulatory and commercial milestones from Incyte.    “This is the fourth antibody from our partnered p...